---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-115077"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:39:30.583076+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Edgewise Q3 net loss $34.1M; Phase 2 CANYON data on track for Dec 2024

## Summary
- Net loss $34.1M ($0.36 per share) vs $31.5M ($0.34) prior quarter; cash $492.5M.
- R&D expenses $32.2M (up $1.5M QoQ); G&A $8.2M (up $0.8M QoQ).
- Top-line CANYON (Becker) data expected December 2024; EDG-7500 28-day data Q1 2025.
- CIRRUS-HCM single dose: 67% mean reduction in resting LVOT gradient; no meaningful LVEF change.
- LYNX (Duchenne) data due Q4 2024; FOX trial over-enrolled within two months.

## SEC filing metadata
- accession: 0001104659-24-115077
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465924115077/0001104659-24-115077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465924115077/tm2427437d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-115077
- JSON: https://secwatch.observer/filing/0001104659-24-115077.json
- Plain text: https://secwatch.observer/filing/0001104659-24-115077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.